Cambridge-based venture capital firm Atlas Venture will split, with its life sciences and technology franchises becoming separate companies. Read more.
Zafgen today announced that it has initiated the first Phase 3 clinical trial, in the United States, with its lead product candidate, beloranib, in the treatment of Prader-Willi syndrome (PWS). PWS is a rare disease and the most common known genetic cause of life-threatening obesity. Read more.